×

Get the Prostate Cancer Patient Guide, available as a free emailed pdf.

Go here to learn more or to get a mailed copy.

Progress Report: Steve Y. Cho, MD

Investigator: Steve Y. Cho, MD – Assistant Professor, Johns Hopkins University Translation of [18F]DCFBC PET:A Novel Prostate Imaging Biomarker Positron Emission Tomography (PET) is a molecular imaging technique that can produce a 3-D image of human cancers. This system works by injecting a patient with a radionuclide tracer (a compound. Read More

Progress Report: Gerhardt Attard, MD, Ph.D

Investigator: Gerhardt Attard, MD, PhD – Assistant Professor, Institute for Cancer Research, Royal Marsden Hospital, London Predicting Resistance to Abiraterone: Molecular Analysis of CTCs First-line treatment for recurrent prostate cancer involves blockade of male hormone (testosterone; androgen) production in a process known as androgen deprivation therapy (ADT). Androgens are synthesized. Read More

Progress Report: Mohamed Simon Arredouani, Ph.D

Investigator: Mohamed Simon Arredouani, PhD – Assistant Professor, Beth Israel Deaconess Medical Center Advances in Prostate Cancer Immunotherapy The immune system protects humans and other mammals from disease by recognizing foreign invaders such as bacteria and viruses. It is also thought that tumor cells express molecules foreign to the patient. Read More

Progress Report: Andrew Armstrong, MD, MSc

Investigator: Andrew Armstrong, MD, MSc – Associate Professor, Duke University Linking Epithelial and Stemness Plasticity with Prostate Cancer Metastasis and the Lethal Phenotype The mechanism by which cancer cells spread from the primary tumor to distant sites in the body (the process of metastasis) is not fully understood. Scientists hypothesize. Read More

Progress Report: John Ward, MD

Investigator: John Ward, MD– Assistant Professor, M.D. Anderson Cancer Center, University of Texas Noninvasive Radiofrequency Field for the Targeted Destruction of Prostate Cancer Using Directed Gold Nanoparticles—Activated Gold Particles Could Provide Novel Means of Destroying Tumors Dr. Ward is investigating a new way to kill prostate cancer cells by targeting. Read More

10/06/2016

How Prostate Cancer is Different in Men of African Descent

If you are a man of African ancestry, prostate cancer needs to be on your radar.  This is because, of all the men in the world, you are in the group that prostate cancer hits the hardest.  Prostate cancer is different in you than it is in other men.  It. Read More

Progress Report: Muneesh Tewari, MD, Ph.D

Investigator: Muneesh Tewari, MD, PhD–Assistant Member, Fred Hutchinson Cancer Research Center, University of Washington Exosomal RNAs as Serum Prostate Cancer Biomarkers—Personalized Treatment and Better Prognostic Indicators May Become Reality Through MicroRNA Tumor Profiling Dr. Tewari and colleagues have discovered that cancer cells shed tiny vesicles from their membrane, much like. Read More

Progress Report: Pier Paolo Pandolfi, MD, Ph.D

Investigator: Pier Paolo Pandolfi, MD, PhD–George C. Reisman Professor of Medicine, Harvard Medical School, Director, Cancer Genetics Program, Associate Director, Cancer Center Beth Israel Deaconess Medical Center Pro-Senescence Therapy for Prostate Cancer The human body has a number of mechanisms in place to protect against cancer growth and survival. One. Read More

Progress Report: David Nanus, MD

Investigator: David Nanus, MD–Professor of Medicine, Professor of Urology, Mark W. Pasmantier Professor of Hematology and Oncology in Medicine at Weill Cornell Medical College Circulating Tumor Cell Biomarker Discovery of Taxotere Response Docetaxel (Taxotere) chemotherapy is the standard first line treatment for patients with castrate resistant prostate cancer (CRPC). Data. Read More

Progress Report: Towia Libermann, Ph.D; Alan Rigby, Ph.D

Co-Investigator: Towia Libermann, PhD–Associate Professor, Medicine, Director, Genomics and Proteomics, Beth Israel Deaconess Medical Center, Harvard Medical School, Director, Dana Farber Cancer Institute Cancer Proteomics Core, Harvard Medical School Co-Investigator: Alan Rigby, PhD–Assistant Professor, Medicine, Director, Program in Drug Discovery and Target Validation, Beth Israel Deaconess Medical Center, Harvard Medical. Read More